These findings suggest that dapagliflozin effectively mitigates the risk of CKD progression in IgAN patients, providing early evidence that SGLT2 inhibitors may serve as a safe and beneficial adjunct to existing standard treatments for IgAN. The gene discussed is SLC5A2; the disease is chronic kidney disease.